NSE: GLENMARK | BSE: 532296

Strong Performer, Getting Expensive

Download real time

2049.20 -36.00 (-1.73%)

60.66% Gain from 52W Low

284.7K NSE+BSE Volume

NSE 22 Sep, 2025 11:50 AM (IST)

57,828.6

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

01 Aug 2017

2049.20

-1.73%

BP Equities Glenmark Pharma Ltd Q1FY18 Result Upd

Buy: Glenmark Pharmaceuticals Ltd.

Recommendation Target

BP Wealth

Glenmark Pharma (GPL) earnings came above our estimate. The company posted revenues of Rs 23.6bn with 20% YoY growth which was above our estimate of Rs 22.8bn. EBITDA margin, at 25.1%, was above our estimate of 22.1% due to favorable product mix . Adj.PAT increased at much higher...

Glenmark Pharmaceuticals Ltd.'s price crossed below 50Day SMA today

Glenmark Pharmaceuticals Ltd.

31 Jul 2017

2049.20

-1.73%

Glenmark Pharmaceuticals

Hold: Glenmark Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

US growth from new launches to offset base business price erosion US generics (~44% of total revenues) grew at ~15% CAGR over FY12-17. Total USFDA filings as on date are 185. So far, the company has received approval for 118. Out of 67 pending ANDAs, ~27 are Para IV applications. Key therapies in the US, going forward, will be oncology dermatology and respiratory. The company expects to file 20-25 ANDAs and launch 1015 ANDAs annually in the US. We expect US sales to remain subdued in FY17-19E to | 3284 (ex-gZetia CAGR ~5% in constant currency), mainly due to higher base and pricing pressure in the US....

Glenmark Pharmaceuticals Ltd. has gained 35.28% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

31 Jul 2017

2049.20

-1.73%

Result Review of Glenmark Pharmaceuticals

Hold: Glenmark Pharmaceuticals Ltd.

IDBI Capital

Q1FY18 revenues increased by 20% YoY lower than our forecast by 7.8%. EBITDA margin of 24.4% were better than our estimates of 21.5%, mainly on the back of better gross margins. However, PAT of Rs3.3bn, +47% YoY, was a beat by 9.5%. For FY18, Glenmark has guided gZetia becoming a USD170-180mn franchise, however, remains confident for a 8-10% YoY growth in revenue in FY18E with EBITDA margins of 22%. For the US region, aims a flat or marginally better revenues in FY18E and signing atleast one out-licensing deal to help reduce debt. Key Highlights and Investment Rationale...

Glenmark Pharmaceuticals Ltd. is trading above its 200 day SMA of 1641.3

Glenmark Pharmaceuticals Ltd.

28 Jul 2017

2049.20

-1.73%

Glenmark (1QFY18): Strong performance. Maintain BUY

Buy: Glenmark Pharmaceuticals Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 1,035 (18x Jun-19E and Rs 135/sh for pipeline). Glenmarks (GNP) 1QFY18 performance was in stark contrast to that in the previous quarter. The overall top-line grew 23% YoY, largely on the back of ~50% growth in the US business (gZetia impact). Revenue was also surprisingly boosted by a 15% growth in the India business, despite the GST disruption in the domestic market. The EBITDA margin came in at 23.3%, in line with estimates, up 640bps YoY. PAT grew ~44% YoY to ~Rs 3.2bn.

Glenmark Pharmaceuticals Ltd. is trading above its 200 day SMA of 1641.3

Glenmark Pharmaceuticals Ltd.

05 Jul 2017

2049.20

-1.73%

Glenmark

Buy: Glenmark Pharmaceuticals Ltd.

Geojit BNP Paribas

New product launches to drive growth amid poor Q4 show Glenmark is an India-based pharmaceutical company with commercial presence in more than 60 countries across the globe. The company derives 63% of total...

Glenmark Pharmaceuticals Ltd. has gained 25.20% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

18 May 2017

2049.20

-1.73%

Result Update:Glenmark Pharma.

Buy: Glenmark Pharmaceuticals Ltd.

Target

Axis Direct

Glenmark's (GNP) Q4 PAT was below estimates due to significant miss in US sales (USD 150 mn vs. estimated USD 193 mn). The sales miss was led by lower gZetia sales (~USD 50 mn vs. est. ~USD 80 mn) and ~15% price erosion in US base business.